Ir para o conteúdo principal

United StatesÚltimas notícias

Grafa

FDA expands approval of Pfizer's HYMPAVZI for hemophilia treatment

Pfizer (NYSE:PFE) announced on June 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted an expanded indication for HYMPAVZI® (marstacimab-hncq). The therapy is now approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with hemophilia A or B, both with and without inhibitors.

Leia mais